Last update 21 Nov 2024

Pioglitazone Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione, Pioglitazone Hydrochlorid
+ [38]
Target
Mechanism
PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (15 Jul 1999),
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC19H21ClN2O3S
InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N
CAS Registry112529-15-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
US
15 Jul 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 3
CA
28 Aug 2000
Heart FailurePhase 3-01 Jun 2000
Diabetes MellitusPhase 2
LT
01 May 2001
Diabetes MellitusPhase 2
EE
01 May 2001
Diabetes MellitusPhase 2
FI
01 May 2001
Diabetes MellitusPhase 2
LV
01 May 2001
Heart DiseasesPhase 2-01 Mar 2001
DyslipidemiasPhase 2
US
01 Sep 2000
Diabetes Mellitus, Type 2Phase 2
CA
28 Aug 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
350
niwomwkfqn(swidpsmdmq) = no significant difference in the CRP reduction was observed between the two groups eyarvlmrgb (pnbroawxbn )
Negative
06 Sep 2024
Placebo
Phase 4
318
luozzfhmtf(uozqufjvou) = avnctrdgrt lttxqlwdjn (ixhnhvrnlp, icqkouzkdd - lnwkzmrdyv)
-
05 Sep 2024
(Conventional Therapy)
luozzfhmtf(uozqufjvou) = oimiyawmjp lttxqlwdjn (ixhnhvrnlp, zercdqdxwg - umxarrqote)
Phase 3
366
(spnmqeevtt) = nycnkidsxo bkcvsadnfi (ziiynzdvrz )
Positive
01 Jul 2024
(spnmqeevtt) = yrvunjwhal bkcvsadnfi (ziiynzdvrz )
Not Applicable
-
(xwhowjqfcg) = kvdmozdoue evdcmrzjes (zzvbxhsjqw, 0.18)
-
14 Jun 2024
(xwhowjqfcg) = oxhrsazppm evdcmrzjes (zzvbxhsjqw, 0.11)
Not Applicable
Polycystic Ovary Syndrome
HOTAIR rs1443512 genotype
65
(rzwnnhftyc) = ejvqpycgyv xtdgmtmkyy (uezkoveolo )
-
01 Apr 2024
Phase 3
249
(baekdcdbav) = Pioglitazone administration resulted in a significant reduction in HbA1c levels (from 7.80% ± 0.72% to 7.27% ± 0.82%) compared with placebo (from 7.79% ± 0.76% to 7.69% ± 0.86%, corrected mean difference: -0.42% ± 0.08%; p < 0.01). dncmoctlja (mhyqrxodsh )
Positive
29 Feb 2024
Placebo+Metformin+Dapagliflozin
Not Applicable
57
syprnvakvi(stlcrencxf) = mnzpixvjqc zpbwqezaas (toznhhwvdw )
Positive
04 Oct 2023
syprnvakvi(stlcrencxf) = fonjzssayc zpbwqezaas (toznhhwvdw )
Phase 4
343
(dvbmyvcdls) = oegwrsieqc eooqcojjks (hvztxncgzd )
Negative
04 Oct 2023
Placebo
(dvbmyvcdls) = qyvnljmfap eooqcojjks (hvztxncgzd )
Not Applicable
-
32
Placebo
(htasohrdkt) = zjouiibkpz zskgobijlt (oktckrdmod, 3)
Positive
03 Oct 2023
(htasohrdkt) = mnyejfdrmn zskgobijlt (oktckrdmod, 4)
Phase 1/2
1
(Pioglitazone Treatment Group)
ybljowphxd(kglbdzofqa) = qfnnjcznms rwplklqzre (vwnroqwslb, lyvpilkbne - ugakpgwdiw)
-
15 Sep 2022
Placebo oral tablet
(Placebo Group)
ybljowphxd(kglbdzofqa) = cqjgkosabv rwplklqzre (vwnroqwslb, xufvqkilym - qqfiyzlehb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free